Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
12. März 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson ...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
05. März 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, March 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28. Februar 2020 16:08 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces Reverse Stock Split
05. Februar 2020 12:45 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
31. Januar 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Official_Bellicum_Logo_RGB.jpg
Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium
24. Januar 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson
21. Januar 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson Current and future GoCAR™ product candidates to be manufactured by MD...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium
16. Januar 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson
11. Dezember 2019 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
08. November 2019 07:00 ET | Bellicum Pharmaceuticals, Inc.
iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling...